Creative Medical Technology (CELZ) Stock Price, News & Analysis

Company Overview

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Key Stats

• Today's Range: $2.20 to $2.34
• 50-Day Range: $2.00 to $2.76
• 52-Week Range: $1.96 to $10.28
• Volume: 30,781 shs
• Average Volume: 33,040 shs
• Market Capitalization: $4.08 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CELZ Stock Analysis - Frequently Asked Questions

How have CELZ shares performed this year?

Creative Medical Technology's stock was trading at $2.31 at the beginning of 2025. Since then, CELZ stock has increased by 0.9% and is now trading at $2.33.
View the best growth stocks for 2025 here.

How were Creative Medical Technology's earnings last quarter?

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) posted its earnings results on Friday, August, 9th. The company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.27. The firm had revenue of $0.01 million for the quarter.

When did Creative Medical Technology's stock split?

Shares of Creative Medical Technology reverse split on Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

How do I buy shares of Creative Medical Technology?

Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Creative Medical Technology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Creative Medical Technology investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), FuelCell Energy (FCEL), Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL) and ChargePoint (CHPT).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 1/21/2025
• Next Earnings (Estimated): 3/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELZ
• CUSIP: N/A
• CIK: 1187953
• Web: www.creativemedicaltechnology.com
• Phone: (833) 336-7636
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.80)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,290,000.00
• Net Margins: N/A
• Pretax Margin: -48,354.54%
• Return on Equity: -63.05%
• Return on Assets: -60.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.13
• Quick Ratio: 19.12

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 407.75
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.48 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 1,750,000
• Free Float: 1,699,000
• Market Cap: $4.08 million
• Optionable: Not Optionable
• Beta: 1.78